Name | [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate |
---|---|
Synonyms |
Ingrezza
(2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate NBI-98854 L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester UNII:54K37P50KH (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-yl L-valinate Valbenazine |
Description | Valbenazine is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function. |
---|---|
Related Catalog | |
In Vivo | Valbenazine shows a distinctive improvement in tardive dyskinesia symptoms during the successful Phase II trial[1]. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 507.2±50.0 °C at 760 mmHg |
Molecular Formula | C24H38N2O4 |
Molecular Weight | 418.569 |
Flash Point | 260.6±30.1 °C |
Exact Mass | 418.283173 |
PSA | 74.02000 |
LogP | 4.31 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.548 |
Storage condition | 2-8℃ |